Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea
Incannex Healthcare reported a net loss of $6.4 million and operating expenses of $6.8 million, with $73.3 million in cash, ensuring a financial runway for at least twelve months. The company made significant progress in its clinical programs, notably with IHL-42X, which reduced the Apnoea-Hypopnoea Index by up to 83% in Phase 2 trials for obstructive sleep apnoea. Preparations for FDA interactions and further studies are underway.
Incannex Healthcare Inc. reported quarter-end cash of $73.3 million, a net loss of $6.4 million, and operating expenses of $6.8 million, supporting at least twelve months of financial runway. During the period, the company advanced its clinical programs, including significant progress with IHL-42X for obstructive sleep apnoea, which showed up to 83.0% reduction in Apnoea-Hypopnoea Index in Phase 2 trials, and PSX-001, which demonstrated meaningful anxiety reduction in Phase 2. Preparations are underway for FDA interactions and further clinical studies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 275311) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
